Categories Earnings, Health Care

Merck’s (MRK) Q3 results beat estimates; sales boosted by oncology and vaccines

Merck (NYSE: MRK) surpassed analysts’ expectations for revenue and earnings in the third quarter of 2019, sending the shares climbing 2.5% in premarket hours on Tuesday.

Worldwide sales rose 15% year-over-year to $12.4 billion, beating estimates of $11.6 billion. Excluding foreign exchange impacts, sales grew 16%. Sales growth was driven by strength in oncology and human health vaccines. 

Merck beats Q3 2019 revenue and earnings estimates

On a GAAP basis, net income fell 3% to $1.9 billion while EPS rose 1% to $0.74. Adjusted net income grew 22% to $3.8 billion. Adjusted EPS increased 27% to $1.51, topping forecasts of $1.24.

Pharmaceutical sales increased 15% year-over-year to $11.1 billion, driven by oncology and vaccines. During the quarter, KEYTRUDA sales grew 62% to $3.1 billion and human health vaccines increased 17% to $2.5 billion. Pharma sales were negatively impacted by the loss of market exclusivity for some products as well as lower sales in JANUVIA and JANUMET.

Animal Health sales grew 10% to $1.1 billion, mainly driven by livestock as well as growth in companion animal products.

Also read: Pfizer Q3 2019 Earnings Report

R&D expenses, on a GAAP basis, increased 55% to $3.2 billion versus the prior-year period, driven mainly by a $982 million charge related to the Peloton acquisition and higher clinical development expenses.

For the full year of 2019, Merck narrowed and raised its revenue guidance to a range of $46.5 billion to $47 billion. This compares to the previous range of $45.2 billion to $46.2 billion. The company narrowed and reduced its GAAP EPS outlook to a range of $3.75-3.80, versus the prior outlook of $3.78-3.88. Merck narrowed and raised its adjusted EPS guidance to a range of $5.12-5.17, which compares to the previous range of $4.84-4.94.   

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Earnings Preview: Fastenal Company likely to report higher Q2 sales and profit

Fastenal Company (NASDAQ: FAST), a leading provider of industrial and construction supplies, is set to publish its second-quarter results next week. The company is among the hardest hit by the

What to look for when Netflix (NFLX) reports its Q2 2025 earnings results

Shares of Netflix, Inc. (NASDAQ: NFLX) stayed red on Monday. The stock has gained 50% over the past three months. The streaming giant is scheduled to report its earnings results

Coinbase shines on stablecoin boom, S&P 500 debut. Will the rally continue?

Coinbase Global, Inc. (NASDAQ: COIN) has emerged as the largest and most user-friendly cryptocurrency exchange in the US, since going public a few years ago. It has played a pivotal

Comments

  1. Pingback: sex webcams
  2. Pingback: linh hoang
  3. Pingback: Festo
  4. Pingback: 스포츠분석
  5. Pingback: 라이브스코어
  6. Pingback: nft
  7. Pingback: esports domains
  8. Pingback: french bulldog
  9. Pingback: aimbot mw2
  10. Pingback: bf2042 ESP
  11. Pingback: candy factory
  12. Pingback: black frenchies
  13. Pingback: elizabeth kerr
  14. Pingback: 늑대닷컴
  15. Pingback: 늑대닷컴
  16. Pingback: dog probiotic
  17. Pingback: crypto news
  18. Pingback: Dog Registry
  19. Pingback: Dog Registry
  20. Pingback: Dog Papers
  21. Pingback: Dog Registry
  22. Pingback: Dog Registry
  23. Pingback: french pitbull dog
  24. Pingback: playnet download
  25. Pingback: playnet
  26. Pingback: golf cart rental

Comments are closed.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top